Journal of Materials Chemistry B · 2016 · 80 citations · 28 references
PharmacyMolecular PharmaceuticsPharmaceuticsDrug DeliveryNanoparticle Drug DeliveryTargeted Drug DeliveryCancer Drug DeliveryNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsNanoparticle DesignDrug Delivery NanocarriersMagnetic NanoparticlesMultifunctional NanoparticlesNanoparticle DeliveryNanoparticle Delivery VectorsNanoparticle-based ChemotherapyNanoparticlesPolymeric Nanocarriers
QD) and combined PTX-curcumin dual-drug treatment, allowing for overcoming drug resistance mechanisms of model multidrug resistant breast cancer cells (MCF-7/ADR). The PTX/MNPs/QDs@Biotin-PEG-PCDA nanoparticles are highly stable under physiological conditions, but are quickly disassembled to release their drug load in the presence of 10 mM glutathione (GSH). The nanoparticles show high uptake by tumour cells from a combined effect of magnet targeting and biotin receptor-mediated internalization. Moreover, curcumin, an intracellularly cleaved product of PCDA, can effectively down regulate the expression of drug efflux transporters such as P-glycoprotein (P-gp) to increase PTX accumulation within target cancer cells, thereby enhancing PTX induced cytotoxicity and therapeutic efficacy against MCF-7/ADR cells. Taken together, this novel tumour-targeting and traceable multifunctional nanomedicine is highly effective against model MDR cancer at the cellular level.
28
Jamaluddin Shaikh, D. D. Ankola, Vikas Beniwal et al. · European Journal of Pharmaceutical Sciences · 2009 · 948 citations
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
John W. Park, Keelung Hong, Dmitri B. Kirpotin et al. · PubMed · 2002 · 648 citations · Full text
Pharmacy, Oncology, Pharmacology +17
Sita Aggarwal, Haruyo Ichikawa, Yasunari Takada et al. · Molecular Pharmacology · 2005 · 530 citations
Medicine, Oncology, Pharmacology +13